KEAP1 and non-small cell lung carcinoma: In addition, given that KEAP1 mutations are common in NSCLC and are associated with poor prognosis and chemoresistance, the combination of artesunate and an NRF2 inhibitor may be a rational and effective combination therapy for future study.